Rituximab (RTX) Therapy in Patients With Active TAO

Summary

Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of life among these patients. The standard treatment for this illness today is intravenous glucocorticoids together with methotrexate. The purpose of this study is to evaluate the effect of rituximab on patients that do not respond to or relapse after conventional therapy.

Timeline

Start

2011-12

Primary completion

2019-09-03

Completion

2020-02-01

Drugs

Indications